Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

omestic) and 1-617-213-8852 (international) prior to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos. A replay of the call will be available Thursday, June 26, 2008, at 12:30 PM ET and will be accessible until Thursday, July 3, 2008, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 27175887.

The conference call will be broadcast simultaneously on the company's Web site, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, and install any necessary software. The call will also be archived on the Vanda Web site for a period of 30 days, through July 26, 2008.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia for which Vanda submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2007. The FDA accepted Vanda's iloperidone NDA for filing in November 2007 and Vanda expects a decision from the FDA on or about July 27, 2008. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Cautionary Note Regarding Forward-Looking Sta
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... A study using a relatively new imaging ... at the composition of carotid artery disease and has ... the disease, a leading cause of stroke. ... September 2010 and May 2012, was featured in the ... American College of Cardiology (JACC) Cardiovascular Interventions. Interventional ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
Breaking Medicine Technology:New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Biostructures, LLC Earns AATB Accreditation 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... Lilly and Company (NYSE: LLY ) today ... for more than three years was published online in ... includes summaries of previously published information; new, previously unpublished ... indicated for the treatment of osteoporosis in postmenopausal women ...
... " Two Years and Counting "   White Paper ... Milestones   and   Educational Needs Elsevier ... more than 1,300 healthcare organizations, today announced the addition of a ... its eBook, A Guide to Education and Training for ICD-10 ...
Cached Medicine Technology:Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 2Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 3Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 4Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 5Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 6Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 2Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013 3
(Date:9/30/2014)... SILVERTHORNE, CO September 30, 2014 Keystone Symposia ... and the first in its 2014-15 Global Health Series ... at the Sheraton Seattle Hotel immediately following the ... grantees. The four-day conference is part of the Keystone ... Melinda Gates Foundation, which has also funded travel awards ...
(Date:9/30/2014)... September 30, 2014 A new study ... University studied the impact of stress on metabolism after eating ... french fries from a fast food restaurant, about 930 calories ... metabolism for 20 minutes every hour for 7 hours, conducting ... that women who had experienced a stressful event in their ...
(Date:9/30/2014)... Integrated Medicine Alliance , Monmouth County’s leader ... specialty practice through a unique partnership with an established ... within the company’s Shrewsbury location and will be staffed ... American Heart Center, P.C., a highly regarded practice located ... Medicine Alliance patients top notch cardiovascular care without leaving ...
(Date:9/30/2014)... Irvine, Calif., Sept. 30, 2014 Research by UC ... system functions, shedding light on a vital process that ... , In the online version of Nature Immunology ... Zhou and other Institute for Immunology colleagues describe a ... and released into the bloodstream. , A T cell ...
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
Breaking Medicine News(10 mins):Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UCI study uncovers important process for immune system development 2Health News:UMD receives inaugural BRAIN Initiative Award 2
... 1, 2011) A groundbreaking new study published in ... in public health spending result in healthier people, especially ... co-authored by Glen P. Mays, the new F. Douglas ... at the University of Kentucky College of Public Health. ...
... Reporter , THURSDAY, Aug. 4 (HealthDay News) -- In 2012, ... will actually drop slightly, U.S. officials announced Thursday. ... prescription drug plan in 2012 will be about $30, a ... representatives of the U.S. Department of Health and Human Services ...
... 4 (HealthDay News) -- People living in a region of ... known to have significantly higher rates of stroke deaths than ... are also at greater risk for sepsis, a severe illness ... examined death rates from sepsis across the United States," said ...
... THURSDAY, Aug. 4 (HealthDay News) -- A growing number of ... clot-busting drug tissue plasminogen activator (tPA) to treat stroke patients ... ischemic stroke is caused by blocked blood flow to the ... who say they,re comfortable using tPA rose from 73 percent ...
... in the United States spend nearly four times as much ... Canada. Most of the difference stems from the fact that ... the multiple payers in the United States. These findings ... Affairs -- the result of a research collaboration among Weill ...
... that the heart contains cardiac stem cells that can contribute ... is known about the molecules and pathways that regulate these ... is providing insight into one way to coax the cardiac ... by Cell Press in the August 2011 issue of the ...
Cached Medicine News:Health News:Study suggests increase in public health spending results in healthier people 2Health News:No Increase in Medicare Drug Premiums in 2012 2Health News:No Increase in Medicare Drug Premiums in 2012 3Health News:U.S. 'Stroke Belt' May Also Be 'Sepsis Belt' 2Health News:More Neurology Residents Using Clot-Busting Drug for Stroke 2Health News:US physician practices spend 4 times Canadian practices 2Health News:US physician practices spend 4 times Canadian practices 3Health News:Hormone reduces risk of heart failure from chemotherapy 2
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
... you can enjoy the ... of the most technically ... gloves on the market. ... provide the needed barrier ...
... The Siegel MAST Intraoperative Leg Positioner frees the ... the need for 2nd assistants to hold the ... on the procedure instead of leg positioning. The ... place the leg in any position required for ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,475-5) ...
Medicine Products: